AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Serial Number: 09/762,594

Filing Date: June 22, 2001

Title:

DNA ENCODING PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR ASSOCIATED PROTEIN 7, AND APPLICATIONS

Page 5

Dkt: 1941.015US1

AND METHODS OF USE

## REMARKS

This responds to the Office Action mailed on December 14, 2004.

Claims 43-44, 46-47, 57-64 and 69-82 are presently canceled; claims 1-9, 17-40, 42, 45, 53-56, 65-68 were previously canceled; as a result, claims 10-16, 41 and 48-52 are now pending in this application. Applicants reserve the right to pursue the canceled claims in a continuation application at a later date.

## Examiner Interview Summary

Applicants' attorney of record, Katherine Jackson-Huebsch (Reg. No. 47,670), conducted a telephonic interview with Examiner Bridget E. Bunner on or about March 1, 2005 regarding the outstanding objections in this application. The Examiner is thanked for the courtesies extended to Applicants' attorney during the interview. The above account is believed to be a complete and accurate summary of the telephonic interview as required by 37 C.F.R. §1.133. If the Examiner believes that this summary is inaccurate or incomplete, Applicants respectfully request that the Examiner point out any deficiencies in her next communication so that Applicants can amend or supplement the interview summary.

## Specification

The specification has been amended to add a Statement of Government Funding.

#### §112 Rejections

As Applicants have canceled claims 43-44, 46-47, 57-64 and 69-82, the rejections of these claims under 35 U.S.C. §112, first paragraph are now moot, and withdrawal of these rejections is respectfully requested.

#### Allowable Subject Matter

In the Final Office action, the Examiner indicated that claims 10-16, 41 and 48-52 were allowable. The Examiner is respectfully requested to pass these claims to issuance.

Page 6 Dkt: 1941.015US1

Serial Number: 09/762,594

Filing Date: June 22, 2001

DNA ENCODING PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR ASSOCIATED PROTEIN 7, AND APPLICATIONS

AND METHODS OF USE

# **CONCLUSION**

Applicants respectfully submit that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicants' attorney (612) 349-9580 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

ZHI-XING YAO ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 349-9580

Date 14 2003

y \_\_\_\_\_/*Y* 

Patti J. Jurkovich

Reg. No. 44,813

<u>CERTIFICATE UNDER 37 CFR 1.8:</u> The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop RCE, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>14th</u> day of <u>June, 2005.</u>

CANDIS BUENDING	Clusho Smuch	
Name	Signature	